



Artimplant AB  
Hulda Mellgrens gata 5  
SE-421 32 Västra Frölunda  
SWEDEN

Phone +46 (0)31 746 56 00  
Fax +46 (0)31 746 56 60  
Web [www.artimplant.com](http://www.artimplant.com)  
Reg. No. 556404-8394

Press Release  
Västra Frölunda, Sweden, September 26, 2007

## **Artimplant AB clears royalty rights for Artelon®**

---

**The biomaterials company Artimplant clears royalty rights for the biomaterial Artelon®. With effect from January 1, 2007 this improves Artimplant's margin on license income from product sales by five percentage points.**

Artimplant AB clears royalty rights for the basic patent for the biomaterial platform Artelon®. The present holder, Polyrand AB, receives SEK 2,750,000 to clear the agreement containing the rights. With effect from January 1, 2007 this improves Artimplant's margin on license income from product sales by five percentage points. Artimplant currently receives license income from Small Bone Innovations, Inc. in respect of sales of Artelon® Spacer and from Biomet Sports Medicine in respect of sales of SportMesh™ Soft Tissue Reinforcement. The payment to Polyrand will be charged to Artimplant's cash reserves and will be recorded as a patent investment during the fourth quarter of 2007.

Polyrand AB was founded by the late Per Flodin, the person behind the basic patent for Artelon®. Per Flodin was professor emeritus in polymer technology at Chalmers University of Technology.

---

### **For further information, please contact:**

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, [hans.rosen@artimplant.com](mailto:hans.rosen@artimplant.com)

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,  
[lars-johan.cederbrant@artimplant.com](mailto:lars-johan.cederbrant@artimplant.com)

Website: [www.artimplant.com](http://www.artimplant.com)

### **Artimplant**

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

### **Forward-looking statements**

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.